By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

1801 Augustine Cut-Off

Wilmington  Delaware  19803  U.S.A.
Phone: 1-855-446-2983 Fax: n/a


Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our first commercial product, Jakafi®, is approved in the U.S. for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Science and Innovation

At Incyte, science drives success. Our world-class expertise, investment in sound and precise science, and our rigorous pursuit of R&D drive our efforts to identify new molecules with the potential to improve the lives of patients, make a difference in health care, and build sustainable value for all our stakeholders.


We are committed to positively impacting the lives of patients with cancer and other diseases. Our clinical research is held to the highest standards of scientific and ethical rigor and we strive to implement programs and initiatives to remove any possible barriers to access for our medicines.

Compliance and Transparency

We aim to make a difference—for patients, medical professionals, organizations, the broader healthcare community and all our global stakeholders. To achieve these goals, we are committed to conducting business ethically. We hold ourselves accountable to the highest standards to ensure that all of our interactions are conducted appropriately. We regularly review and amend our practices according to our own standards, as well as the standards required of us by the communities in which we live and work.

Our Global Community

We exist to improve the lives of people facing life-altering and life-threatening diseases like cancer, and actively support various local and global initiatives that are health-related or benefit the communities in which we live and work.

We strive to comply with all laws and regulations that govern environmental, health and safety matters and to sustainable business practices.

Key Statistics

Ownership: Public

Web Site: Incyte
Symbol: INCY

Company News
Massachusetts Agenus (AGEN) Gets a Sweetened $510 Million Deal From Incyte (INCY) 2/14/2017 5:44:52 AM
Incyte (INCY) And Calithera Biosciences (CALA) Announce Global Collaboration To Develop And Commercialize CB-1158, A First-In-Class, Small Molecule Arginase Inhibitor 1/30/2017 9:40:38 AM
Bay Area's Calithera Biosciences (CALA) Rockets After Getting $53 Million Upfront in Cancer Deal With Incyte (INCY) 1/30/2017 5:30:29 AM
Incyte (INCY) Who? Why This Biotech Would Give Gilead (GILD) a Bang for Its Buck 1/26/2017 6:19:56 AM
Incyte (INCY) Release: Company To Report Fourth Quarter And Year-End Financial Results 1/24/2017 7:55:29 AM
Eli Lilly (LLY)-Incyte (INCY) Release: The FDA Wants More Time to Review Baricitinib 1/16/2017 6:38:41 AM
Incyte (INCY) And Merck & Co. (MRK) To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA (Pembrolizumab) 1/9/2017 10:47:30 AM
Incyte (INCY) Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi) In Graft-versus-Host Disease 1/3/2017 9:52:41 AM
Incyte (INCY) Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease 12/30/2016 2:28:38 PM
Taking a Shot on Who Might Buy Incyte (INCY) in 2017 12/27/2016 7:31:51 AM